182 related articles for article (PubMed ID: 35882728)
1. Polyethylene Glycol 3350 (PEG 3350) as a Practical Vehicle for Rapid Reconstitution of PARPi-FL Formulations for Clinical Use.
Demétrio de Souza França P; Viray T; Roberts S; Michel A; Abrahão M; Patel SG; Ganly I; Schöder H; Brand C; Reiner T; Pillarsetty NVK
Mol Imaging Biol; 2023 Apr; 25(2):294-302. PubMed ID: 35882728
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer.
Demétrio de Souza França P; Kossatz S; Brand C; Karassawa Zanoni D; Roberts S; Guru N; Adilbay D; Mauguen A; Valero Mayor C; Weber WA; Schöder H; Ghossein RA; Ganly I; Patel SG; Reiner T
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3618-3630. PubMed ID: 33954826
[TBL] [Abstract][Full Text] [Related]
3. Detection and Delineation of Oral Cancer With a PARP1-Targeted Optical Imaging Agent.
Kossatz S; Weber W; Reiner T
Mol Imaging; 2017; 16():1536012117723786. PubMed ID: 28856922
[TBL] [Abstract][Full Text] [Related]
4. PARP1-targeted fluorescence molecular endoscopy as novel tool for early detection of esophageal dysplasia and adenocarcinoma.
Marcazzan S; Braz Carvalho MJ; Nguyen NT; Strangmann J; Slotta-Huspenina J; Tenditnaya A; Tschurtschenthaler M; Rieder J; Proaño-Vasco A; Ntziachristos V; Steiger K; Gorpas D; Quante M; Kossatz S
J Exp Clin Cancer Res; 2024 Feb; 43(1):53. PubMed ID: 38383387
[TBL] [Abstract][Full Text] [Related]
5. PARPi-FL--a fluorescent PARP1 inhibitor for glioblastoma imaging.
Irwin CP; Portorreal Y; Brand C; Zhang Y; Desai P; Salinas B; Weber WA; Reiner T
Neoplasia; 2014 May; 16(5):432-40. PubMed ID: 24970386
[TBL] [Abstract][Full Text] [Related]
6. Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent.
Kossatz S; Brand C; Gutiontov S; Liu JT; Lee NY; Gönen M; Weber WA; Reiner T
Sci Rep; 2016 Feb; 6():21371. PubMed ID: 26900125
[TBL] [Abstract][Full Text] [Related]
7. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
Rabenau K; Hofstatter E
Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
[TBL] [Abstract][Full Text] [Related]
8. Optical Imaging of PARP1 in Response to Radiation in Oral Squamous Cell Carcinoma.
Kossatz S; Weber WA; Reiner T
PLoS One; 2016; 11(1):e0147752. PubMed ID: 26808835
[TBL] [Abstract][Full Text] [Related]
9. Fluorescence-guided resection of tumors in mouse models of oral cancer.
Demétrio de Souza França P; Guru N; Roberts S; Kossatz S; Mason C; Abrahão M; Ghossein RA; Patel SG; Reiner T
Sci Rep; 2020 Jul; 10(1):11175. PubMed ID: 32636416
[TBL] [Abstract][Full Text] [Related]
10. Clinical PARP inhibitors allosterically induce PARP2 retention on DNA.
Langelier MF; Lin X; Zha S; Pascal JM
Sci Adv; 2023 Mar; 9(12):eadf7175. PubMed ID: 36961901
[TBL] [Abstract][Full Text] [Related]
11. Nanoemulsion-Based Delivery of Fluorescent PARP Inhibitors in Mouse Models of Small Cell Lung Cancer.
Gonzales J; Kossatz S; Roberts S; Pirovano G; Brand C; Pérez-Medina C; Donabedian P; de la Cruz MJ; Mulder WJM; Reiner T
Bioconjug Chem; 2018 Nov; 29(11):3776-3782. PubMed ID: 30354077
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma.
Vormoor B; Curtin NJ
Curr Opin Oncol; 2014 Jul; 26(4):428-33. PubMed ID: 24840521
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-ribose) polymerase inhibitor therapeutic effect: are we just scratching the surface?
Hottiger MO
Expert Opin Ther Targets; 2015; 19(9):1149-52. PubMed ID: 26212149
[TBL] [Abstract][Full Text] [Related]
14. The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance.
Pham MM; Hinchcliff E; Avila M; Westin SN
Cancer J; 2021 Nov-Dec 01; 27(6):491-500. PubMed ID: 34904812
[TBL] [Abstract][Full Text] [Related]
15. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
[TBL] [Abstract][Full Text] [Related]
16. Preclinical and first-in-human-brain-cancer applications of [
Young RJ; Demétrio De Souza França P; Pirovano G; Piotrowski AF; Nicklin PJ; Riedl CC; Schwartz J; Bale TA; Donabedian PL; Kossatz S; Burnazi EM; Roberts S; Lyashchenko SK; Miller AM; Moss NS; Fiasconaro M; Zhang Z; Mauguen A; Reiner T; Dunphy MP
Neurooncol Adv; 2020; 2(1):vdaa119. PubMed ID: 33392502
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
Tentori L; Ricci-Vitiani L; Muzi A; Ciccarone F; Pelacchi F; Calabrese R; Runci D; Pallini R; Caiafa P; Graziani G
BMC Cancer; 2014 Mar; 14():151. PubMed ID: 24593254
[TBL] [Abstract][Full Text] [Related]
18. Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma.
Carlucci G; Carney B; Brand C; Kossatz S; Irwin CP; Carlin SD; Keliher EJ; Weber W; Reiner T
Mol Imaging Biol; 2015 Dec; 17(6):848-55. PubMed ID: 25895168
[TBL] [Abstract][Full Text] [Related]
19. Poly(ADP-Ribose) Polymerase-1 Inhibitors Drug Discovery, Design, and Development as Anticancer Agents from Past to Present: A Mini-Review.
AlGhamdi A; AlMubayedh H
Mini Rev Med Chem; 2022; 22(12):1597-1606. PubMed ID: 34587882
[TBL] [Abstract][Full Text] [Related]
20. PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer.
Liu C; Li J; Xu F; Chen L; Ni M; Wu J; Zhao H; Wu Y; Li J; Wu X; Chen X
Mol Cancer; 2024 May; 23(1):111. PubMed ID: 38778348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
